Kazia Therapeutics Limited

NasdaqCM KZIA

Kazia Therapeutics Limited Market Capitalization on January 14, 2025: USD 7.70 M

Kazia Therapeutics Limited Market Capitalization is USD 7.70 M on January 14, 2025, a 434.95% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Kazia Therapeutics Limited 52-week high Market Capitalization is USD 29.53 M on November 11, 2024, which is 283.22% above the current Market Capitalization.
Kazia Therapeutics Limited 52-week low Market Capitalization is USD 836.54 K on July 09, 2024, which is -89.14% below the current Market Capitalization.
Kazia Therapeutics Limited average Market Capitalization for the last 52 weeks is USD 5.24 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: KZIA

Kazia Therapeutics Limited

CEO	Dr. John Edwin Friend II, M.D.
IPO Date	Jan. 6, 1999
Location	Australia
Headquarters	Three International Towers
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key trends

Past 5 years